Abstract
We found increased levels of atherosclerosis-inducing homocysteine in parkinsonian patients with long-term application of levodopa compared with previously untreated parkinsonian patients and controls. We conclude that antiparkinsonian treatment with levodopa promotes occurrence of vascular disease in Parkinson's disease.
MeSH terms
-
Aged
-
Antiparkinson Agents / adverse effects*
-
Carboxy-Lyases / antagonists & inhibitors
-
Female
-
Homocysteine / blood*
-
Humans
-
Levodopa / adverse effects*
-
Male
-
Middle Aged
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / metabolism
-
Substantia Nigra / drug effects*
-
Substantia Nigra / metabolism
-
Vascular Diseases / chemically induced*
Substances
-
Antiparkinson Agents
-
Homocysteine
-
Levodopa
-
Carboxy-Lyases